Peptide News Digest

#Neuroendocrine

2 stories

Clinical Trials · View digest

Perspective Therapeutics' Alpha-Emitter PRRT Hits 43% ORR in Neuroendocrine Tumors at AACR

Perspective Therapeutics' [212Pb]VMT-α-NET, a first-in-class alpha-emitter peptide radionuclide therapy targeting SSTR2, achieved objective responses in 10 of 23 (43%) Cohort 2 patients with metastatic neuroendocrine tumors in Phase 1/2a data presented at AACR 2026. 18 of 25 patients (72%) remained alive without progression; no dose-limiting toxicities or Grade 4/5 adverse events observed.

Industry · View digest

Pheochromocytoma Market Forecast: Lutathera PRRT Peptide-Radionuclide Therapy Drives 7.3% CAGR Through 2036

A DelveInsight market analysis published April 20 projects 7.3% CAGR growth in the pheochromocytoma and paraganglioma treatment market through 2036, driven by SSTR2 analogs and peptide receptor radionuclide therapies including Novartis's Lutathera (lutetium-177 dotatate). PRRT remains one of the few FDA-approved peptide therapeutics for rare neuroendocrine tumors, binding SSTR2 to deliver targeted radiation.